News
Current report No. 49/2021 – Change in the composition of the Management Board of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (hereinafter: the “Company”) hereby informs that today it has been notified of Ms Iwona Giedronowicz’s resignation from the position of member of the Company’s Management Board. Ms Iwona Giedronowicz held the position of member of the Company’s Management Board and Chief Financial Officer since 2014.
Current report No. 48/2021 – Celon Pharma S.A.’s project on the development of innovative therapeutic solutions with the use of RNA technology is granted co-funding
The Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on November 29, 2021 it received information that the Company’s application for co-funding of the project entitled “TransformRNA – mRNA Therapeutics generation platform” (the “Project”) submitted to the competition announced by the Medical Research Agency for the commercial clinical trials entitled “Development of innovative therapeutic solutions using RNA technology” (ABM/2021/5), has been selected for co-funding.
Current report No. 47/2021 – Commencement of a phase II clinical trial of a drug based on the innovative JAK/ROCK inhibitor – CPL 409116 – in the treatment of rheumatoid arthritis (RA)
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on 19 November 2021 it submitted an application to the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products for consent to commence a phase II clinical trial of this compound.
Current report No. 46/2021 – Notification about a transaction on subscription warrants of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on November 5, 2021 it received a notification from the person discharging managerial responsibilities in the Company – Mr Jacek Glinka, Vice President of the Company’s Management Board
Current report No. 45/2021 – Allocation of A series subscription warrants to eligible persons under Incentive Programs for Members of the Management Board and other persons of key importance to the Company
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on November 2, 2021 the Supervisory Board and the Management Board of the Company assigned 30,000 A series subscription warrants (“Warrants”) in total to the eligible persons who had made relevant subscriptions; each Warrant entitles them to subscribe for 1 C series share of the Company at the issue price of PLN 0.10 per share.
The results of CPL’36 – PDE10a inhibitor to be presented in the poster session at Neuroscience 2021.
This year, from November 8-11, the jubilee, 50th edition of the conference organized by the Society for Neuroscience – the world’s largest organization of scientists and doctors dealing with brain diseases will take place. Despite the fact that the event is planned in the online formula, the organizers have planned numerous lectures, poster sessions andRead more »
Celon Pharma S.A. at the Jefferies Healthcare Conference 2021.
Representatives of the Management Board of Celon Pharma S.A. will take part in the 12th edition of the largest European conference on life science.
Current report No. 44/2021 – Adoption of Regulations and implementation of Incentive Programs for Members of the Management Board and other persons of key importance to the Company
The Management Board of Celon Pharma S.A. The “Company” hereby informs that on October 15, 2021 the Supervisory Board and the Management Board of the Company adopted resolutions on the adoption of Regulations of Incentive Programs directed at Members of the Management Board and the Company’s Officers, respectively, and that the implementation of the aforementioned Incentive Programs has already commenced.
Current report No. 43/2021 – Notification about transactions on shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on October 8, 2021, Glatton Sp. z o.o. – a person closely related to the person discharging managerial responsibilities, i.e. Mr. Maciej Wieczorek – President of the Management Board of Celon Pharma S.A., sent a notification on transactions conducted on the Company’s shares.
Doubled export sales, continuation of the strategy of investing in research and development
Net revenue from total sales in the first half of 2021 totalled PLN 105 million. Mostly due to export sales, which exceeded domestic sales. The majority of the Company’s products have maintained their market share in Poland, while the dynamic of the entire drug market in Poland has been decreasing.